Johns Hopkins Diabetes Guide
Bethanechol
INDICATIONS
FDA
FDA
- Urinary Retention: Treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Neurogenic bladder
- Gastroparesis
- Alzheimer’s disease
- Gastric reflux
- Gastric atony or adyamic ileus
- Erectile dysfunction
- Motion sickness
- Stuttering
- Treatment of disabling anticholinergic adverse effects or anticholinergic syndrome from medications such as tricyclic antidepressants
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: February 6, 2022
Citation
Veillard, Régine B, et al. "Bethanechol." Johns Hopkins Diabetes Guide, 2022. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547017/all/Bethanechol.
Veillard RB, Elder Dalpoas S, Samal L. Bethanechol. Johns Hopkins Diabetes Guide. 2022. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547017/all/Bethanechol. Accessed May 30, 2023.
Veillard, R. B., Elder Dalpoas, S., & Samal, L. (2022). Bethanechol. In Johns Hopkins Diabetes Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547017/all/Bethanechol
Veillard RB, Elder Dalpoas S, Samal L. Bethanechol [Internet]. In: Johns Hopkins Diabetes Guide. ; 2022. [cited 2023 May 30]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547017/all/Bethanechol.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Bethanechol
ID - 547017
A1 - Veillard,Régine,Pharm.D., BCACP TTS
AU - Elder Dalpoas,Stacy,Pharm.D., BCPS
AU - Samal,Lipika,M.D.
Y1 - 2022/02/06/
BT - Johns Hopkins Diabetes Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Diabetes_Guide/547017/all/Bethanechol
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
